Phase 2 Study of Neoadjuvant Treatment with Cellular Redox Modulator NOV-002 in Combination with Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) in Patients with Stage II-III HER-2 (-) Breast Cancer

被引：0
|
作者：
Montero, A. J.
Diaz, C. M.
Slingerland, J.
Pegram, M.
Hurley, J.
Welsh, C. F.
Avisar, E.
Seo, P.
Vogel, C. L.
Garrett-Mayer, E.
Hermann, V.
Baker, M. K.
Silva, O.
Koniaris, L.
Rodgers, S.
Schuhwerk, K.
Pazoles, C. J.
Moffat, F.
Cole, D. J.
Gluck, S.
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Coral Gables, FL 33124 USA
[2] Med Univ S Carolina, Charleston, SC USA
[3] Novelos Therapeut, Newton, MA USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P1-11-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-05
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER+ HER2- Breast Cancer: A Prospective Phase II Study
    Hayashi, Naoki
    Yagata, Hiroshi
    Tsugawa, Koichiro
    Kajiura, Yuka
    Yoshida, Atsushi
    Takei, Junko
    Yamauchi, Hideko
    Nakamura, Seigo
    CLINICAL BREAST CANCER, 2020, 20 (06) : 462 - 468
  • [42] Neoadjuvant treatment of stage II or III breast cancer with docetaxel and low dose capecitabine, with addition of trastuzumab for HER 2 amplified tumors
    Khan, Q. J.
    Sharma, P.
    Kimler, B. F.
    Baranda, J.
    Andersen, J. C.
    Klemp, J.
    Fabian, C. J.
    BREAST, 2007, 16 : S49 - S49
  • [43] Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+breast cancer: A BrUOG study
    Sinclair, Natalie Faye
    Sakr, Bachir Joseph
    Abu-Khalaf, Maysa M.
    Somlo, George
    Black, Robert C.
    Chung, Gina G.
    Rizack, Tina
    Strenger, Rochelle
    Fenton, Mary Anne
    DiGiovanna, Michael
    Constantinou, Maria
    Lannin, Donald R.
    Legare, Robert Duffy
    Chagpar, Anees B.
    Sambandam, Sundaresan T.
    Bossuyt, Veerie
    Rosati, Kayla
    Harris, Lyndsay
    Sikov, William M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] HER2 overexpression predicts survival in stage II and III of breast cancer patients treated with neoadjuvant docetaxel plus epirubicin
    不详
    VIRCHOWS ARCHIV, 2005, 447 (02) : 364 - 365
  • [45] Liposome-encapsulated doxorubicin plus cyclophosphamide followed by trastuzumab plus docetaxel as neoadjuvant therapy for HER2-positive breast cancer (BC): A multicenter single-arm phase II study
    Saracchini, Silvana
    Foltran, Luisa
    Sulfaro, Sandro
    Tuccia, Fausto
    Del Conte, Alessandro
    Bertolla, Manuella
    Bassini, Anna
    Micheli, Elvia
    Manente, Stefania
    Gusso, Giuseppina
    Baresic, Tania
    Tumoio, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study
    Tampaki, Ekaterini C.
    Tampakis, Athanasios
    Alifieris, Constantinos E.
    Krikelis, Dimitrios
    Pazaiti, Anastasia
    Kontos, Michalis
    Trafalis, Dimitrios T.
    CLINICAL DRUG INVESTIGATION, 2018, 38 (07) : 639 - 648
  • [47] Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study
    Ekaterini C. Tampaki
    Athanasios Tampakis
    Constantinos E. Alifieris
    Dimitrios Krikelis
    Anastasia Pazaiti
    Michalis Kontos
    Dimitrios T. Trafalis
    Clinical Drug Investigation, 2018, 38 : 639 - 648
  • [48] Doxorubicin and cyclophosphamide followed by weekly docetaxel (AC-T) as neoadjuvant chemotherapy in operable breast cancer patients: Interim results from the 2002-03 GEICAM study
    Estevez, Laura G.
    Adrover, Encarna
    Barnandas, Agusti
    Cuevas, Jose M.
    Segui, Miguel A.
    ANNALS OF ONCOLOGY, 2004, 15 : 65 - 66
  • [49] Neoadjuvant trastuzumab and sequential chemotherapy with cisplatin, vinorelbine, and docetaxel for stage II-III breast cancer patients: Final results of a single institution phase II study.
    Carillio, Guido
    Aiello, Rosa Anna
    Chiarenza, Maurizio
    Ali, Marco
    Mazzola, Antonella
    Di Marco, Rosanna
    Taibi, Eleonora
    Fallica, Giuseppina
    Casella, Tiziana
    Zacchia, Alessandra
    Castiglione, Gaetano
    Caruso, Francesco
    Caruso, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Effect of adding TS-1 to neoadjuvant chemotherapy in HER2-negative, stage II-III breast cancer in a single-arm phase II study
    Lee, S.
    Moon, Y.
    Park, B.
    Kim, S. I.
    Park, S.
    Kim, J.
    Choi, H. J.
    Sohn, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345